IMPLANET Announces the Implementation of the OSD Acquisition
18 Mai 2021 - 5:45PM
Business Wire
- All resolutions were adopted at today’s Combined General
Meeting
- Strengthening of the new entity’s governance
Regulatory News:
IMPLANET (Paris:ALIMP) (Euronext Growth: ALIMP, FR0013470168,
eligible for PEA-PME equity savings plans), a medical technology
company specializing in vertebral and knee-surgery implants,
informs its shareholders that its Combined General Meeting was held
in closed session on Tuesday May 18 at 2 pm CEST at the Company’s
head offices in Martillac, just outside Bordeaux.
The number of shares held by the shareholders present or
represented was 1,734,493, giving a quorum of 22.98%.
All of the resolutions tabled at this Combined General Meeting
were passed, and notably those pertaining to the acquisition of
Orthopaedic & Spine Development (“OSD”), endorsing the
immediate implementation of its planned integration within
Implanet. The appointment of OSD’s founders, Nicolas Papillon and
Benjamin Letienne, as Members of the Board of Directors was also
approved.
Ludovic Lastennet, Implanet’s CEO, said: “I would like to
thank all of our shareholders who were present, were represented or
voted online or by post for their commitment and participation.
Their contribution enabled us to complete the acquisition of OSD,
thus strengthening Implanet’s positioning as a new heavyweight in
spine surgery in France. This merger opens the way for numerous
value-creating synergies and will contribute to the new entity
achieving its strategic targets, i.e. continue innovating to
enhance our implant range, continue expanding our certifications
and approvals and strengthen the sales organization. I am delighted
to welcome, as members of our Board of Directors, the CEO and the
Managing Director of OSD to further strengthen the Group’s
governance”.
The minutes of the Combined General Meeting and a replay of the
webinar will be made available on the Company’s website within the
statutory timeframe.
Upcoming financial events:
- H1 2021 revenue, July 6, 2021 after market
- H1 2021 results, September 21, 2021 after market
About Implanet
Founded in 2007, Implanet is a medical technology company that
manufactures high-quality implants for orthopedic surgery. Its
activity revolves around two product ranges, the latest generation
JAZZ® implant, designed to improve the treatment of spinal
pathologies requiring vertebral fusion surgery, and the MADISON
implant designed for first-line prosthetic knee surgery. Implanet’s
tried-and-tested orthopedic platform is based on product
traceability. Protected by four families of international patents,
JAZZ® and MADISON have obtained 510(k) regulatory clearance from
the Food and Drug Administration (FDA) in the United States, the CE
mark as well as the ANVISA authorization in Brazil. Implanet
employs 29 staff and recorded 2020 sales of €6.0 million. For
further information, please visit www.implanet.com. Based near
Bordeaux in France, Implanet established a US subsidiary in Boston
in 2013. Implanet is listed on Euronext™ Growth market in
Paris.
The Company would like to remind that the table for monitoring
the equity line (OCA, OCAPI, BSA) and the number of shares
outstanding, is available on its website:
http://www.implanet-invest.com/suivi-des-actions-80
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210518005922/en/
IMPLANET Ludovic Lastennet, CEO David Dieumegard, CFO
Tel.: +33 (0)5 57 99 55 55 investors@Implanet.com
NewCap Investor Relations Mathilde Bohin
Nicolas Fossiez Tel.: +33 (0)1 44 71 94 94
Implanet@newcap.eu
NewCap Media Relations Nicolas Merigeau
Tel.: +33 (0)1 44 71 94 94 Implanet@newcap.eu
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024